Chronic Myeloid Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
ARIAD prices common stock public offering

ARIAD prices common stock public offering

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

ARIAD's oral ridaforolimus improves PFS in patients with metastatic endometrial cancer

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Otsuka opens Canadian operations

Otsuka opens Canadian operations

Novartis applauds declaration of CML Awareness Day in Canada

Novartis applauds declaration of CML Awareness Day in Canada

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

CAS researchers confirm Gleevec’s first generation drug targets chronic myelogenous leukemia

CAS researchers confirm Gleevec’s first generation drug targets chronic myelogenous leukemia

US oncology announces its contributions in development of 42 novel cancer therapies

US oncology announces its contributions in development of 42 novel cancer therapies

Tasigna receives approval for chronic myeloid leukemia in Canada

Tasigna receives approval for chronic myeloid leukemia in Canada

Fertility preservation may be unsafe for leukemia patients: Study

Fertility preservation may be unsafe for leukemia patients: Study

ARIAD reports $159.3 million second-quarter net income

ARIAD reports $159.3 million second-quarter net income

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Prostate basal cell can spawn tumors in prostate gland: Research

Prostate basal cell can spawn tumors in prostate gland: Research

New test to predict suitable treatment for chronic myeloid leukemia patients

New test to predict suitable treatment for chronic myeloid leukemia patients